AFX Stock Overview
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AFX from our risk checks.
Carl Zeiss Meditec AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €174.60 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.90 |
| 1 Month Change | 0.029% |
| 3 Month Change | 0.029% |
| 1 Year Change | 0.029% |
| 3 Year Change | 37.37% |
| 5 Year Change | 81.40% |
| Change since IPO | 572.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| AFX | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 0% | -3.5% | -2.1% |
| 1Y | 0.03% | 4.7% | -3.6% |
Return vs Industry: AFX underperformed the Swiss Medical Equipment industry which returned 4.7% over the past year.
Return vs Market: AFX exceeded the Swiss Market which returned -3.6% over the past year.
Price Volatility
| AFX volatility | |
|---|---|
| AFX Average Weekly Movement | 0.008% |
| Medical Equipment Industry Average Movement | 3.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: AFX has not had significant price volatility in the past 3 months.
Volatility Over Time: AFX's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1846 | 4,823 | Markus Weber | www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.
Carl Zeiss Meditec AG Fundamentals Summary
| AFX fundamental statistics | |
|---|---|
| Market cap | CHF8.48b |
| Earnings (TTM) | CHF268.84m |
| Revenue (TTM) | CHF2.03b |
31.6x
P/E Ratio4.2x
P/S RatioIs AFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFX income statement (TTM) | |
|---|---|
| Revenue | €2.09b |
| Cost of Revenue | €893.14m |
| Gross Profit | €1.20b |
| Other Expenses | €924.07m |
| Earnings | €276.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 3.09 |
| Gross Margin | 57.35% |
| Net Profit Margin | 13.22% |
| Debt/Equity Ratio | 7.2% |
How did AFX perform over the long term?
See historical performance and comparison